Are Anaplastic Lymphoma Kinase Gene Rearrangements in Non-Small Cell Lung Cancer Prognostic, Predictive, or Both?

Journal of Thoracic Oncology - United States
doi 10.1097/jto.0b013e31823f1289
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Alectinib in Untreated Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Annals of Translational Medicine
Medicine
2017English

Clinical Challenges in Targeting Anaplastic Lymphoma Kinase in Advanced Non-Small Cell Lung Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2014English

Expanding Anaplastic Lymphoma Kinase Therapeutic Indication to Early Stage Non-Small Cell Lung Cancer

Translational Lung Cancer Research
Oncology
2019English

Diagnostic Assays for Identification of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2012English

Anaplastic Lymphoma Kinase (ALK) Inhibitors for Second-Line Therapy of Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2012English

Correlation of Anaplastic Lymphoma Kinase Overexpression and the EML4-ALK Fusion Gene in Non-Small Cell Lung Cancer by Immunohistochemical Study

Biomedical Journal
Medicine
2012English

Prognostic Gene Signatures for Non-Small-Cell Lung Cancer

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

P3.13-04 Lorlatinib in Anaplastic Lymphoma Kinase and Proto-Oncogene Tyrosine-Protein Kinase ROS-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.15-16 ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy